The collaboration leverages the Inovalon MORE 2 Registry® payer-sourced dataset and Corrona’s platform of clinical registries to enable data-driven insights on the treatment of autoimmune diseases from both clinical and health economic perspectives. Avalere, an Inovalon company specializing in...Learn More
8-13 November, 2019 | Atlanta, GA
American College of Rheumatology Annual Meeting
20-24 March, 2020 | Denver, CO
American Academy of Dermatology Annual Meeting
2-5 May, 2020 | Chicago, IL
Digestive Disease Week Annual Meeting
3-6 June, 2020 | Frankfurt, Germany
EULAR: Annual European Congress of Rheumatology 2020
News
Mar 17 2020 - 7:00am
News
May 20 2019 - 10:00am
WALTHAM, Mass., May 20, 2019 PRNewswire -- Corrona, LLC is pleased to announce a key milestone for the Corrona® Multiple Sclerosis (MS) Registry, a real-world US-based registry developed as a collaborative effort with the National MS Society. The collaborative registry model now includes Genentech...Learn More
News
Dec 11 2017 - 8:00am
Portland, Ore. (December 11, 2017) — The Corrona® Psoriasis Registry , a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC , the leading sponsor of registries in autoimmune and immune-mediated diseases, announces it has expanded into Canada and has enrolled its...Learn More
News
Oct 20 2017 - 7:15am
WALTHAM, Mass., Oct. 20, 2017 /PRNewswire/ -- Corrona, LLC and the National Multiple Sclerosis Society have announced their intent to collaborate on the launch of the Corrona Multiple Sclerosis (MS) Registry to study the comparative safety and effectiveness of approved MS therapies. The first...Learn More
News
Sep 14 2017 - 8:00am
According to results of an observational analysis, the efficacy of adalimumab is sustained in rheumatoid arthritis (RA) patients who continued therapy for 10 years. Biologic-naïve RA patients who had enrolled in the Corrona RA registry after initiating adalimumab during follow-up were included in...Learn More
News
Aug 14 2017 - 10:30am
by Ed Susman, Contributing Writer, MedPage Today ORLANDO -- Rheumatoid arthritis (RA) patients who received tocilizumab (Actemra) with methotrexate achieved low disease activity and could discontinue methotrexate while maintaining disease control, researchers said here. In a study designed to...Learn More